Peregrine's Vascular Targeting Agent Inhibits Growth of Breast Cancer Tumor Metastases by 50 Percent in Pre-Clinical Studies

Peregrine Maintains Listing On Russell 2000 And 3000 IndexesR

Peregrine's Vasopermeation Enhancement Agent Technology Highlighted In The Lancet Oncology

Peregrine Announces Fiscal Year 2003 Year End Results And Operational Highlights

Peregrine Pharmaceuticals Receives Over $4 Million in Cash

Peregrine's Vasopermeation Enhancement Agent Technology Highlighted In Nature Reviews Cancer

Peregrine's Phosphatidylserine Based Vascular Targeting Agent Technology Presented at the Angiogenesis II Conference in Paris, France

Peregrine and Affitech to Collaborate on Developing Fully Human Vascular Targeting Agent Antibodies

Peregrine Regains Compliance with Nasdaq Listing Requirements

Peregrine Pharmaceuticals Raises Over $2 Million From Institutional Investors; $1.5 Million In Debt Converted